AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19722444 — intervention group
Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, and drying (group 4)
Number of subjects: 56
Study 19722444 — intervention group
Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, and rinsing/drying (group 5)
Number of subjects: 56
Study 19722444 — intervention group
Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, drying, SE primer, and drying (group 6)
Number of subjects: 56
Study 19722444 — intervention group
Group type: EXPERIMENTAL
Intervention: SE primer, drying, saliva, rinsing/drying, SE primer, and drying (group 7)
Number of subjects: 56
Study 17976094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (4 grams)
Number of subjects: 229
Study 17976094 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ibutilide without magnesium
Number of subjects: 229
Study 17976094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (1 to 3 grams)
Number of subjects: 229
Study 17976094 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive magnesium
Number of subjects: 229
Study 14973335 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary-context condition (egocentric and/or allocentric coding)
Number of subjects: 0
Study 14973335 — intervention group
Group type: EXPERIMENTAL
Intervention: Moved-context condition (allocentric coding)
Number of subjects: 0
Study 14973335 — intervention group
Group type: COMPARATOR
Intervention: No-context condition (egocentric condition)
Number of subjects: 0
Study 11989569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 40
Study 11989569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9376454 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 33
Study 9376454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8186350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg at breakfast
Number of subjects: 202
Study 8186350 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 202
Study 3285638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg dexamethasone
Number of subjects: 72
Study 3285638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 72
Study 3285638 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 72
Study 3285638 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline
Number of subjects: 72
Study 29908088 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interlocking suture group
Number of subjects: 36
Study 29908088 — intervention group
Group type: COMPARATOR
Intervention: Criss-cross suture group
Number of subjects: 36
Study 29908088 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative flap thickness
Number of subjects: 36
Study 29908088 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of discomfort
Number of subjects: 36
Study 27004280 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions (DIG)
Number of subjects: 25
Study 27004280 — intervention group
Group type: COMPARATOR
Intervention: Conventional pick-up (CIG)
Number of subjects: 25
Study 25582962 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load group
Number of subjects: 0
Study 25582962 — intervention group
Group type: COMPARATOR
Intervention: Low cognitive load group
Number of subjects: 0
Study 25582962 — intervention group
Group type: COMPARATOR
Intervention: No image guidance
Number of subjects: 0
Study 25582962 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireframe overlay
Number of subjects: 0
Study 25582962 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid overlay
Number of subjects: 0
Study 24026991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) with wavelength of 78 nm and 2.5 j/cm2, two times a week for 5 min, for one month
Number of subjects: 60
Study 24026991 — intervention group
Group type: COMPARATOR
Intervention: Sham laser therapy
Number of subjects: 60
Study 20586368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask Me 3 pamphlet
Number of subjects: 0
Study 19359232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy with 1 500 IU of antitetanus serum and 1.5 g of intravenous metronidazole daily
Number of subjects: 42
Study 19359232 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of 9 000 IU of antitetanus serum (4 500 IU cutaneously and 4 500 IU intramuscularly)
Number of subjects: 42
Study 16176204 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (2-9 mg/day, average 5.9 mg)
Number of subjects: 10
Study 16176204 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg acute exposure)
Number of subjects: 10
Study 16176204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12949309 — intervention group
Group type: COMPARATOR
Intervention: Control formula (n = 65)
Number of subjects: 197
Study 12949309 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with DHA (n = 65)
Number of subjects: 197
Study 12949309 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with both ARA and DHA (n = 66)
Number of subjects: 197
Study 12949309 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed group (n = 80)
Number of subjects: 197
Study 10856393 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide withdrawal
Number of subjects: 32
Study 10856393 — intervention group
Group type: COMPARATOR
Intervention: Furosemide continued
Number of subjects: 32
Study 8785137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during mild hypoxia (PE'O2 6.2 kPa)
Number of subjects: 8
Study 8785137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during moderate hypoxia (PE'O2 5.7 kPa)
Number of subjects: 8
Study 8785137 — intervention group
Group type: COMPARATOR
Intervention: Control (1 min isocapnic hypoxia, PE'O2 6.1 kPa)
Number of subjects: 8
Study 8785137 — intervention group
Group type: COMPARATOR
Intervention: Control (1 min normoxic VHV)
Number of subjects: 8
Study 8785137 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC) during normoxic VHV
Number of subjects: 8
Study 1354276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose 60 g daily in four doses by mouth for 3 days
Number of subjects: 20
Study 1354276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6686117 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 1.05 rad X s‐1 (group S)
Number of subjects: 21
Study 6686117 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 3.14 rad X s‐1 (group I)
Number of subjects: 21
Study 6686117 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at 5.24 rad X s‐1 (group F)
Number of subjects: 21
Study 30913976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Gaming System for aphasia
Number of subjects: 17
Study 30913976 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 17
Study 30280657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib (180 mg once daily with a 7-day lead-in period at 90 mg)
Number of subjects: 275
Study 30280657 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 275
Study 30280657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 275
Study 30280657 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 275
Study 26944023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg
Number of subjects: 600
Study 26944023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 25188501 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM 400 mg
Number of subjects: 340
Study 25188501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 22640674 — intervention group
Group type: EXPERIMENTAL
Intervention: Connecticut intrusion arch
Number of subjects: 45
Study 22640674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implant system
Number of subjects: 45
Study 22640674 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 45
Study 19263026 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination Centres for Clinical Trials (KKS)
Number of subjects: 0
Study 17957155 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 months of life
Number of subjects: 37
Study 17957155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic administration)
Number of subjects: 37
Study 15586515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivicaine via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Number of subjects: 45
Study 15586515 — intervention group
Group type: COMPARATOR
Intervention: Saline solution via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Number of subjects: 45
Study 11683310 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia module
Number of subjects: 174
Study 11683310 — intervention group
Group type: COMPARATOR
Intervention: Customary Instruction (Control)
Number of subjects: 174
Study 9574889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate (as an additive to Acarosan)
Number of subjects: 118
Study 9574889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 9574889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate
Number of subjects: 118
Study 7933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex criteria by Zwiebel
Number of subjects: 120
Study 7933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex criteria by Strandness
Number of subjects: 120
Study 7933267 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic velocity > 270 cm/sec and end diastolic velocity > 110 cm/sec
Number of subjects: 120
Study 3340474 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of MMR, DTP, and OPV vaccines
Number of subjects: 815
Study 3340474 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of MMR followed by booster doses of DTP and OPV 2 months later
Number of subjects: 815
Study 31302023 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring efficacy training
Number of subjects: 100
Study 31302023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 4 μg·kg‐1·min‐1 (M3)
Number of subjects: 300
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 2 μg·kg‐1·min‐1 (M1)
Number of subjects: 300
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine 3 μg·kg‐1·min‐1 (M2)
Number of subjects: 300
Study 28599629 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 300
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including M3)
Number of subjects: 300
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 and M2
Number of subjects: 300
Study 28599629 — intervention group
Group type: EXPERIMENTAL
Intervention: M3
Number of subjects: 300
Study 27421049 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based testing services
Number of subjects: 9
Study 27421049 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinics established for TasP
Number of subjects: 9
Study 27421049 — intervention group
Group type: COMPARATOR
Intervention: Linkage to HIV clinics
Number of subjects: 9
Study 27421049 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals to HIV clinics
Number of subjects: 9
Study 24589564 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral abdominal adipose tissue (VAT)
Number of subjects: 425
Study 24589564 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT)
Number of subjects: 425
Study 24589564 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal adipose tissue (SAT)
Number of subjects: 425
Study 24589564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic fat fraction (HFF)
Number of subjects: 425
Study 23040830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 874
Study 23040830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 19536915 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 12-week treatment with varenicline
Number of subjects: 377581
Study 19536915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377581
Study 17638657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprobe-assisted lumpectomy
Number of subjects: 6
Study 15273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic conjugate polysaccharide vaccine against Hib
Number of subjects: 0
Study 15273395 — intervention group
Group type: COMPARATOR
Intervention: Licensed products prepared with Hib polysaccharide extracted from bacteria
Number of subjects: 0
Study 11136307 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy incision
Number of subjects: 100
Study 11136307 — intervention group
Group type: COMPARATOR
Intervention: Scalpel incision
Number of subjects: 100
Study 10223783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg BMS‐186716
Number of subjects: 9
Study 10223783 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fosinopril
Number of subjects: 9
Study 7872185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 52
Study 7872185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 60 mg
Number of subjects: 52
Study 7872185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 7872185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (combined 40 mg and 60 mg)
Number of subjects: 52
Study 2309993 — intervention group
Group type: EXPERIMENTAL
Intervention: SULLA 808 V (Drägerwerk AG, Lübeck)
Number of subjects: 4
Study 2309993 — intervention group
Group type: COMPARATOR
Intervention: AV 1 (Drägerwerk AG, Lübeck)
Number of subjects: 4
Study 2309993 — intervention group
Group type: COMPARATOR
Intervention: ELSA (Gambro Engström AB, Bromma, Sweden)
Number of subjects: 4
Study 2309993 — intervention group
Group type: COMPARATOR
Intervention: VIVOLEC (Hoyer Medizintechnik, Bremen)
Number of subjects: 4
Study 359019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienylic acid (500 mg)
Number of subjects: 11
Study 359019 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg)
Number of subjects: 11
Study 359019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienylic acid and Hydrochlorothiazide
Number of subjects: 11
Study 359019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienylic acid
Number of subjects: 11
Study 31990615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 101
Study 31990615 — intervention group
Group type: COMPARATOR
Intervention: Community Treatment by Experts
Number of subjects: 101
Study 30948365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (sHD) - 2 weekly 3-day blocks with cytarabine 2 g/m2 twice a day for 2 days plus idarubicin
Number of subjects: 574
Study 30948365 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy
Number of subjects: 574
Study 30948365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (sHD)
Number of subjects: 574
Study 28166521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (daily split doses titrated to tolerance: 30/15, 45/15, 60/30, or 90/30 mg) for 12 months
Number of subjects: 1370
Study 28166521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1370
Study 28166521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1370
Study 26703660 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month evidence-based diabetes self-management intervention
Number of subjects: 65
Study 24288221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: plastic stents changed every 3 months or sooner if symptoms appeared
Number of subjects: 78
Study 24288221 — intervention group
Group type: COMPARATOR
Intervention: Group B: plastic stents changed on demand at the onset of symptoms
Number of subjects: 78
Study 24288221 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: plastic stents changed every 3 months
Number of subjects: 78
Study 24288221 — intervention group
Group type: COMPARATOR
Intervention: Group B: plastic stents changed on demand
Number of subjects: 78
Study 21781648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg taken orally thrice daily)
Number of subjects: 40
Study 21781648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Diclofenac (75 mg taken orally twice daily)
Number of subjects: 40
Study 21781648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac Epolamine Topical Patch (DETP, 1.3% applied topically twice daily)
Number of subjects: 40
Study 21781648 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 mg/2 min intravenously)
Number of subjects: 40
Study 19041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation (intermediate and definitive)
Number of subjects: 77
Study 19041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (increasing doses)
Number of subjects: 77
Study 19041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 77
Study 17563030 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD + virgin olive oil
Number of subjects: 372
Study 17563030 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD + nuts
Number of subjects: 372
Study 17563030 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 372
Study 14646402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg once a day)
Number of subjects: 22
Study 14646402 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study 11605698 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d)
Number of subjects: 494
Study 11605698 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride
Number of subjects: 494
Study 11605698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 9608463 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic fixation (group A)
Number of subjects: 60
Study 9608463 — intervention group
Group type: COMPARATOR
Intervention: Non-anatomic fixation (group B)
Number of subjects: 60
Study 7916039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) at 3,900 mg/m2 with cyclophosphamide (7.2 g/m2), carmustine (600 mg/m2), etoposide (2.4 g/m2)
Number of subjects: 33
Study 7916039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) at 3,900 mg/m2 with CBV regimen
Number of subjects: 33
Study 1590872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg intracervically)
Number of subjects: 81
Study 364357 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 64
Study 364357 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 31589087 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSE Theater® (experimental group, n = 44)
Number of subjects: 77
Study 31589087 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 77
Study 27451978 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase (ASP) treatment
Number of subjects: 1285
Study 27451978 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase (ASP) re-exposure
Number of subjects: 1285
Study 27451978 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent insulin therapy
Number of subjects: 1285
Study 27451978 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent abdominal pain
Number of subjects: 1285
Study 27451978 — intervention group
Group type: COMPARATOR
Intervention: Germline DNA genotyping for ULK2 variant rs281366
Number of subjects: 1285
Study 27451978 — intervention group
Group type: COMPARATOR
Intervention: Germline DNA genotyping for RGS6 variant rs17179470
Number of subjects: 1285
Study 25527735 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (2 × 150 ml of 1% w/v tea/day)
Number of subjects: 43
Study 25527735 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 43
Study 23620111 — intervention group
Group type: EXPERIMENTAL
Intervention: IMOUTA handoff method
Number of subjects: 0
Study 23620111 — intervention group
Group type: COMPARATOR
Intervention: Traditional handoff method
Number of subjects: 0
Study 16688105 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing using Odontoson M
Number of subjects: 60
Study 16688105 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with Odontoson M irrigated with a 10% iodised solution
Number of subjects: 60
Study 16688105 — intervention group
Group type: COMPARATOR
Intervention: Curettage using Gracey curettes
Number of subjects: 60
Study 15607620 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 568
Study 15607620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 568
Study 10390663 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (5-7.5 mg)
Number of subjects: 150
Study 10390663 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (5-7.5 mg)
Number of subjects: 150
Study 9014793 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (10 mg per day)
Number of subjects: 40
Study 9014793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1569240 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac
Number of subjects: 145
Study 1569240 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac
Number of subjects: 145
Study 1569240 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg ketorolac
Number of subjects: 145
Study 1569240 — intervention group
Group type: COMPARATOR
Intervention: 50 mg meperidine
Number of subjects: 145
Study 1569240 — intervention group
Group type: COMPARATOR
Intervention: 100 mg meperidine
Number of subjects: 145